BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 25, 2007
 |  BioCentury  |  Product Development

Crossing the cancer divide

Based on their mechanism, some nucleoside analogs are predisposed to work well in hematologic cancers, while others fare much better against solid tumors, but few have been able to address both.

Based on Phase I data presented this month at the American Society of Clinical Oncology meeting, Cyclacel Pharmaceuticals Inc. (CYCC, Berkeley Heights, N.J.) plans to pursue both in parallel. A Phase II trial in cutaneous T cell lymphoma that started in April could offer the company an abbreviated path to market and should help to inform the design of trials for lung cancer.

Sapacitabine (CYC682) is a nucleoside analog licensed in 2003 from Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan). According to CYCC President and CEO Spiro Rombotis, the most relevant comparator "in terms of mechanism, chemical structure and apparent toxicity" is Gemzar from Eli Lilly and Co. Inc. (LLY, Indianapolis, Ind.), which is approved to treat breast, lung, ovary and pancreatic cancers.

Both are cell cycle inhibitors...

Read the full 815 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >